anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
3,5-Diiodo acetyl salicylic acid is reacted with ethyl chloroformate in a mixt. of triethylamine and acetone and the mixed anhydride formed is reacted in situ with 4-amino 2-chloro alpha-(4-chloro phenyl) 5-methyl phenyl acetonitrole of formula (II) in dimethyl formamide. The solvents are removed by evaporation in vacuum, the product hydrolysed with an aq. soln. of alkali or alkaline earth carbonate or bicarbonate for 2 h. at 50-60 deg. C and finally acidified to a pH not below 5, the water removed in vacuum and the product purified by crystallisation to give the salicylamide deriv. of formula (I).
PURPOSE:To simply perform the separation of serum without damaging vital information, by constituting the titled separator so that a corpuscle component and a serum component are separated by providing a separation module hollow fiber bundle to a vacuum blood sampling tube. CONSTITUTION:Collected whole blood 1 is put in a vacuum blood sampling tube 2 and a module case 6 is inserted into said sampling tube 2. A separation module hollow fiber bundle 3 is provided in the case 6 and hollow fibers are opened at the upper seal part 4 of said fiber bundle 3. A serum component flow passage 5 opened in a filtering side is provided to the lower seal part 4' of the fiber bundle 3 and communicated with a serum component receiver 8. The lower end parts of the hollow fibers are communicated with a corpuscle component receiver 7. When the whole blood 1 is collected in the vacuum blood sampling tube 2 and filtering is performed by pressing the blood sampling tube 2 and the case 6, the corpuscle component is stored in the corpuscle component receiver 7 through the hollow fiber bundle 3 and the serum component is filtered by the hollow fiber bundle 3 and stored in the receiver 8 through the flow passage 5. Because the module hollow fiber bundle is used, the corpuscle component and the serum component can be rapidly separated.
The study is a prospective, multicenter, two-armed, randomised clinical trial that will be coordinated from the Department of Cardiology, Herlev-Gentofte Hospital. The primary objective of the study is to determine whether a new digital strategy can be implemented to introduce novel medical therapies, specifically sodium-glucose co-transporter-2 (SGLT-2) inhibitors to heart failure patients. The aim is to increase the number of eligible patients who initiate therapy and to reduce the time taken to initiate therapy compared to the current process. The study will recruit patients with a registered diagnosis of heart failure residing in The Capital Region of Denmark and Roskilde, who have not yet been started on SGLT-2 inhibitor therapy. Patient identification and recruitment will be carried out through Danish nationwide registries, using their personal identification number (CPR-number), which is also linked to a secure digital mailbox where all official letters from public authorities are sent to Danish citizens. Patients will be randomly assigned (1:1) to receive a digital letter containing evidence-based information about the newly approved heart failure therapy option, SGLT-2 inhibitors. The letter will also invite recipients to be evaluated by a heart failure specialist for potential initiation of the therapy. Outcome measures will be obtained from Danish nationwide registers at pre-specified time points and in collaboration with the Danish Health Data Authority.
The ACT intervention consists of 6 manual-based face-to-face sessions and internet-based homework modules. The manual is based on the six core processes in the ACT-model: acceptance, mindfulness, defusion, self as context, values and committed action.
PROBLEM TO BE SOLVED: To obtain a dental composition for the pretreatment of a teeth surface and having a high adhesivity, which comprises separately wrapped two agents, i.e., a liquid agent prepared by dissolving an acidic group-containing polymeric monomer in a specific ether compound and a liquid agent mainly composed of water and is used by mixing the two agents directly before application. SOLUTION: Two agents, i.e., an agent containing a solution prepared by dissolving an acidic group-containing polymerizable monomer in a water-soluble ether compound having no OH group as a basic component and an agent containing water as a basic component are separately wrapped, and the both agents are mixed directly before application. The dental composition is optionally compounded further with a polymerization stimulator. A straight ether compound having no polymerizable group is preferable as the water-soluble ether compound having no OH group. The compounding ratio of the ether compound is preferably 5-80wt.%, especially preferably about 10-70wt.%. As an example of the acidic group contained in the polymerizable monomer, a phosphoric acid group, a carboxylic acid group, a sulfonic acid group, etc., is cited.  The compounding ratio of the monomer is preferably 2-75wt.%, especially preferably about 7-40wt.%.
PROBLEM TO BE SOLVED: To improve molding fidelity and the smoothness of the surface of cured matter by adding and mixing specific pts.wt. of specific kinds of compds. selected from caffein anhydrous and its deriv. as well as nicotinic acid and its deriv. into and with specific pts.wt. of hemihydrated gypsum. SOLUTION: One or >=2 kinds selected from the group consisting of the caffein anhydrous and its deriv. as well as the nicotinic acid and its deriv. are added at 0.05 to 5.0 pts.wt., more preferably about 0.1 to about 4.0 pts.wt. to 100 pts.wt. hemihydrated gypsum. For example, about 0.1 pt.wt. caffein anhydrous is dispersed and mixed into and with 100 pts.wt. dental hard gypsum powder and the mixture is injected to an impression surface and is cured. The surface roughness of the cured matter of the gypsum obtd. in such a manner is about 0.5Raμm while that of the case of non-addition is about 1.2Raμm. As a result, the surface smoothness is improved.
Three sessions of aerobic exercise per week (outdoor walking), for 50 continuous minutes, at moderate intensity (Identified by the Borg Subjective Perception of Exertion Scale, scores from 12 to 13), will be performed for 7 weeks. These sessions will be accompanied by a researcher responsible for data collection, who will make a daily record of the activities. The practice time will be between 5:00 pm and 7:00 pm.
FID 120947A contact lens disinfecting solution used with soft contact lenses (study lenses) on a daily basis for 180 days. SCL preservative solution used standard-of-care.
PURPOSE:A plaster which is liquid in application, shows a filmy state by drying after application and has improved water resistance and flexibility, containing a water-soluble high polymer, a polyhydric alcohol and a drug. CONSTITUTION:A plaster containing (A) a water-soluble high polymer such as PVA, polyvinylpyrrolidone, 2-hydroxyethyl (meth)acrylate (co)polymer, CMC or gum arabic, (B) a polyhydric alcohol such as polyethylene glycol, glycerin, etc., and (C) a drug which is absorbed with time to show medicinal effects. The amount of the component B used is 10-200pts.wt., preferably 20-70pts.wt. based on 100pts.wt. component A. Since the plaster shows a filmy state by drying, the plaster is not attached to materials to be brought into contact with the agent, the affected part is not exposed to air and causes no problem of reduction in active ingredient of drug resulting from adhesion to the materials and reduction in medicinal effects.
NEW MATERIAL:An antibiotic SF2575 substance. USE:Useful as an antitumor agent. The substance exhibits an antibacterial activity against a kind of gram-positive bacteria and further a strong antitumor action against mouse leukemia P-388. PREPARATION:A SF2575 substance-producing bacterium belonging to the genus Streptomyces is cultured and the SF2575 substance is collected from the cultured product. Known nutritive sources heretofore utilized for the culture of Actinomyces bacteria can be used as nutritive sources for the above culture. A culturing method under an aerobic condition, especially a deep culturing method is most suitable as the culturing method of the bacterium. The culturing temperature is approximately 28 deg.C in many cases. The novel SF2575 substance has the following characteristics. Pale yellow needle-like crystals; melting point: 191-193 deg.C; molecular formula: C40H43NO15; elementary analysis: C 61.41%, H 5.68% and N 1.64%; soluble in methanol, ethyl acetate etc., and insoluble in n-hexane.
The proposed MultiComponent TeleRehabilitation (MCTR) program addresses current healthcare deficiencies by using a multicomponent approach that includes both high-intensity rehabilitation interventions and self-management interventions that are not part of traditional physical therapy interventions. Therefore, the investigators propose a two-arm, parallel randomized trial using a crossover study design to determine the effectiveness (AIM 1) of a 12-week multicomponent telerehabilitation program to improve physical function. The investigators will also measure Veterans' clinical outcomes to evaluate the effectiveness of the MCTR program to improve physical activity, health self-management, and self-reported health (AIM 2). Lastly, the investigators will explore the effects of the MCTR program on safety events such as emergency room visits, hospitalizations, falls, and other adverse events (AIM 3). Participants (n=126) will be randomized to MCTR or Control group using computer-generated random blocks, stratified by sex. The MCTR group will participate in the 24-week program consisting of 1) progressive, high-intensity rehabilitation, 2) self-management interventions, 3) social support, and 4) technology supports. The 12-week program is split into three phases: the Active Phase (weeks 1-6), the Transition Phase (weeks 7-12), and the Sustainability Phase (weeks 13-24). The Control group will participate in education and health status update sessions in parallel to the MCTR 12-week program. Outcomes will be collected at baseline, 6 weeks, 12 weeks (primary endpoint), and 24 weeks. Achievement of the proposed aims will provide evidence to expand high quality telerehabilitation services for medically complex older Veterans with multiple factors contributing to poor health (e.g., social isolation, loneliness, physical inactivity, poor self-management). Importantly, results will guide the advancement of rehabilitation practices, moving away from a traditionally narrow, episodic, diagnosis-focused approach to a model emphasizing whole health self-management and sustained healthy living. Study findings will have immediate clinical impact as they will be directly translatable to other medically complex and underserved populations who will benefit from innovative telerehabilitation care approaches.
The purpose of this study is to determine the contribution of hydroxyproline metabolism to urinary oxalate and glycolate excretion in patients with primary hyperoxaluria.

Oxalic acid (COOH)2 is an end product of metabolism that is synthesized mainly in the liver. The researchers have estimated that 10 - 20 mg is synthesized in the body of healthy adults each day. The main precursor of oxalate is glyoxylate (CHO•COOH). The bulk of the glyoxylate formed is normally transaminated to glycine (NH2•CH2•COOH) by alanine: glyoxylate aminotransferase (AGT) or reduced to glycolate (CHOH•COOH) by glyoxylate reductase (GR). Less than 10% of the glyoxylate is oxidized to oxalate by lactate dehydrogenase (LDH). In individuals with the disease, primary hyperoxaluria, AGT, GR, or hydroxy-oxoglutarate aldolase (HOGA) enzyme is deficient and the amount of oxalate synthesized by the liver increases to 80 - 300 mg per day. The increased oxalate excreted in urine can cause damage to kidney tissue. Calcium oxalate stones may form in the kidney or calcium oxalate crystals may deposit in renal tubules and the renal parenchyma (nephrocalcinosis). An increased rate of oxalate synthesis could also contribute to idiopathic calcium oxalate stone disease. Understanding the pathways of endogenous oxalate synthesis and identifying strategies that decrease oxalate production could be beneficial for individuals with these diseases.

Hydroxyproline is the primary source of glyoxylate identified in the body. Daily collagen turnover of bone results in the formation of 300 - 450 mg of hydroxyproline, which cannot be re-utilized by the body and is broken down. This metabolism yields 180 - 250 mg of glyoxylate. Further hydroxyproline is obtained from the diet, primarily from meat and gelatin-containing products. The bulk of the glyoxylate formed is converted to glycine by the liver enzyme AGT, some to glycolate and a small amount to oxalate. The proportion of these metabolites is not known with any certainty. In this study, a quantitative estimate of the metabolites formed will provide estimates of the contribution of hydroxyproline turnover to daily oxalate production.
Chronic expanding hematoma (CEH) is defined as a hematoma that gradually expands over months to years. An 82-year-old female underwent proton radiotherapy for left upper lobe lung cancer 10 years previously. Two years after the therapy, a hematoma developed from the left 3rd to 5th dorsal rib fractures and gradually expanded, causing contraction of the left shoulder. Transcatheter arterial embolization was performed; however, the hematoma continued to expand with thrombocytopenia, and the platelet was decreased to 4.2 × 104/μL. Computed tomography showed a 17.2 × 14.0 × 10.0 cm mass between the left scapula and left dorsal ribs. The CEH of the thorax was completely excised with combined resection of the 3rd to 5th ribs, while the brachial plexus was preserved. Postoperatively, the platelet completely recovered and she could raise her left arm. A complete excision with surrounding organs preserved is the strategy used in the treatment of CEH of the thorax.
The invention discloses a hydroxysafflor yellow A oil solution. By weight, the hydroxysafflor yellow A oil solution is composed of 0.2%-5% hydroxysafflor yellow A, 84%-95.3% of carbon chain triacylglycerol and 4%-15% of granulesten. The hydroxysafflor yellow A oil solution has the advantages of being large in medicine carrying amount, small in partial irritation and high in bioavailability. The invention further discloses a preparation method of the hydroxysafflor yellow A oil solution. The preparation method of the hydroxysafflor yellow A oil solution is simple, good in repeatability, convenient to control and capable of achieving volume production. The invention further discloses application of the hydroxysafflor yellow A oil solution in preparing hydroxysafflor yellow A soft capsules.
This article presents a case of severe CPR-related injuries leading to diagnosis of vascular Ehlers-Danlos syndrome. The subject is a 36-year-old female with a past medical history of a 10-mm aneurysm of the right internal carotid artery discovered on imaging 3 years prior to death. Major autopsy findings included subarachnoid hemorrhage in the base of the brain, bilateral hemothoraces, hemopericardium, laceration of the interatrial septum, laceration of the left pulmonary artery, and changes secondary to chronic alveolar hemorrhage in the lungs. The autopsy findings and subsequent unremarkable toxicology studies led to the suspicion of an underlying and clinically undiagnosed connective tissue disorder. Broad genetic exome testing revealed a mutation consistent with vascular Ehlers-Danlos syndrome. An overview of this disease, its diagnosis, and differential are further described herein, along with recommendations for forensic pathologists.
Neuroinflammation is a key driver of neurodegenerative disease, however the tools available to model this disease biology at the systems level are lacking. We describe a translational drug discovery platform based on organotypic culture of murine cortical brain slices that recapitulate disease-relevant neuroinflammatory biology. After an acute injury response, the brain slices assume a chronic neuroinflammatory state marked by transcriptomic profiles indicative of activation of microglia and astrocytes and loss of neuronal function. Microglia are necessary for manifestation of this neuroinflammation, as depletion of microglia prior to isolation of the brain slices prevents both activation of astrocytes and robust loss of synaptic function genes. The transcriptomic pattern of neuroinflammation in the mouse platform is present in published datasets derived from patients with amyotrophic lateral sclerosis, Huntington's disease, and frontotemporal dementia. Pharmacological utility of the platform was validated by demonstrating reversal of microglial activation and the overall transcriptomic signature with transforming growth factor-β. Additional anti-inflammatory targets were screened and inhibitors of glucocorticoid receptors, COX-2, dihydrofolate reductase, and NLRP3 inflammasome all failed to reverse the neuroinflammatory signature. Bioinformatics analysis of the neuroinflammatory signature identified protein tyrosine phosphatase non-receptor type 11 (PTPN11/SHP2) as a potential target. Three structurally distinct inhibitors of PTPN11 (RMC-4550, TN0155, IACS-13909) reversed the neuroinflammatory disease signature. Collectively, these results highlight the utility of this novel neuroinflammatory platform for facilitating identification and validation of targets for neuroinflammatory neurodegenerative disease drug discovery.
All participants will be re-randomized after study week 6. Those participants assigned to Aftercare Group B will receive contingency management treatment plus standard treatment for weeks 7-12.
Coronary obstruction (CO) is a potential pitfall for transcatheter aortic valve replacement (TAVR), especially in valve in valve procedures into degenerated surgical or transcatheter prostheses. Bioprosthetic leaflet modification techniques that incorporate electrosurgery are evolving as the preferred strategy to mitigate the risk of CO in high CO risk settings. The UNICORN method is proposed as a more predictable leaflet modification strategy than the earlier described BASILICA approach, but its proponents have hitherto mandated the use of a balloon-expandable valve (BEV) prosthesis. Many patients have small prostheses and therein face a significant risk of patient prosthesis mismatch with BEV in this setting. This risk may be curtailed if a self-expanding valve (SEV) prosthesis could be used. Herein described is a modified approach to allow for the utilization of SEV systems in this setting.
AZT has been shown to be effective in HIV-related disease. IL-2 has been shown to increase immune responses and correct immune problems caused by HIV in the test tube. IL-2 has also been effective in treating Kaposi's sarcoma in a number of patients. Because of the clinical activities of these two drugs and because their toxicities and mechanisms of action do not overlap, it may be beneficial to combine the two drugs with their antiviral and immune stimulatory effects.

Patients enter the study in staggered groups of five. All patients receive AZT orally every 4 hours for 12 weeks. At the end of 8 weeks, the first group of five patients receive the lowest dosage of IL-2 on a daily basis while still receiving AZT. Toxicity and immunologic effects are measured at the beginning of AZT therapy and then every 2 weeks. Each succeeding group of five patients receives a higher dose of IL-2, while receiving AZT, until the MTD is reached. Those patients who have shown no toxicity as well as improved immune function while taking both drugs receive a 4-week follow-up course of IL-2 5 weeks after stopping AZT. In addition, five patients who have completed the AZT / IL-2 combined treatment without significant toxicity are re-treated with 12 weeks of AZT alone starting 8 weeks after completing the initial combined AZT / IL-2 portion of treatment. Another five patients will be re-treated with 12 weeks of full dose of AZT alone, followed by 8 weeks of half-dose AZT alone starting 8 weeks after completing the initial combined AZT / IL-2 treatment. Patients receive ibuprofen for fever and chills, and those who reach their MTD continue to receive that dose in combination with AZT for 4 weeks. If excess toxicity is observed on all doses of IL-2, the study will be discontinued.
BACKGROUND: Breast cancer is the most common cancer in women. Progression-free survival for hormone receptor-positive/human epidermal growth factor receptor-2-negative metastatic breast cancer treated with endocrine therapy in combination with cyclin4/6-dependent kinase is approximately 25 months. This case represents metastatic breast cancer treated with endocrine therapy, leading to long-term survival.
CASE PRESENTATION: A 40-year-old Syrian woman diagnosed with hormone receptor-negative breast cancer was treated surgically with adjuvant chemotherapy and radiotherapy. She developed local and nodal recurrences that were hormone receptor-positive, followed by a recurrence of malignant pleural effusion. She was initially treated with chemotherapy and then placed on endocrine therapy with a complete response from 2014 until now. The patient also suffered from adverse events of medications, such as heart failure and osteoporosis, which were treated appropriately.
CONCLUSION: This case demonstrates a long-lasting complete response to metastatic breast cancer with malignant pleural effusion. This shows the validity of endocrine therapy in recurrent hormone receptor-positive breast cancer, especially in countries that cannot afford targeted therapies or genetic tests. It also highlights the necessity for a better understanding of the prognostic and predictive factors.
The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will vary in protein source. All ingredients are GRAS listed and approved. All participants will complete all 12 interventions.
Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 30-60 minutes (beginning after gemcitabine infusion) and bevacizumab IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD), complete response (CR), or partial response (PR) after the sixth course may receive bevacizumab as a single agent once every 3 weeks in the absence of disease progression or unacceptable toxicity.
Anemia is sometimes seen in patients receiving NSAIDs, including nabumetone tablets. This may be due to fluid retention, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including nabumetone tablets, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia.

NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving nabumetone tablets who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored (see CLINICAL PHARMACOLOGY).